Articles tagged with Parkinsons Disease
The Phase 1 trial demonstrated that repeated immunisation with PD01A is safe and well-tolerated, with a substantial reduction in alpha-synuclein oligomers and stable motor scores. The results suggest that PD01A may offer a promising strategy for long-term management of Parkinson's disease.
A new study by UCSF researchers found that weaker or irregular circadian rhythms in daily rest and activity cycles are associated with a greater likelihood of developing Parkinson's disease later on. Disruptions in the brain's internal clock may be an early warning sign of neurodegenerative disease processes.
A study of 3,000 independently living older men found that weak or irregular circadian rhythms are associated with a greater likelihood of developing Parkinson's disease years later. The researchers suggest that these disruptions may reflect neurodegenerative processes already affecting the brain's internal clock.
Researchers at UT Southwestern Medical Center have developed new MRI techniques to more precisely target brain structures linked to Parkinson's disease and essential tremor. These methods, including diffusion tractography, aim to reduce adverse effects associated with previous treatments.
Researchers at McLean Hospital identified two molecules naturally produced by the body that stimulate dopamine production, which may help reverse Parkinson's disease progression. Prostaglandin A1 and E1 protect dopamine-producing neurons from dying and increase dopamine levels without side effects.
A team of researchers has identified potential new therapeutic targets to treat Parkinson's disease by understanding the structure and dynamics of the protein alpha-synuclein. They found that a specific region of the protein becomes more exposed when it aggregates, which can lead to diseases like Parkinson's.
A study by NTU Singapore-Harvard University has identified a promising molecular pair, Prostaglandin E1 and Prostaglandin A1, that can boost dopamine levels and slow Parkinson's disease. The researchers found that these hormone-like substances can activate Nurr1, leading to increased dopamine production and neuroprotection.
A new UCLA study found that chemicals in diesel exhaust can trigger the toxic buildup of alpha-synuclein proteins in brain cells, a common occurrence in people with Parkinson's. The research used zebrafish and human cells to confirm the link between air pollution and brain damage.
A team of investigators from McLean Hospital and Massachusetts General Hospital have successfully reprogrammed a patient's skin cells to replace lost brain cells in Parkinson's disease. The patient has shown significant improvements in daily activities and quality of life after receiving the treatment, which involves transplanting repl...
Neuroscientists at York University developed five predictive models using non-motor clinical and biological variables to detect early-stage Parkinson's disease. The models achieved over 80% accuracy in distinguishing early-stage Parkinson's from healthy controls, offering a potential alternative to traditional diagnosis methods.
A new multi-arm, multi-stage (MAMS) trial platform is proposed to evaluate potential therapies for Parkinson's disease, potentially accelerating the search for a cure. This approach has already been successful in other diseases, such as prostate and renal cancer, and could speed up trials by eliminating unsuccessful treatments early.
Analysis of participants in the Harvard Biomarkers Study reveals an inverse association between low caffeine consumption and higher urate levels with reduced risk of Parkinson's disease. The study suggests that both caffeine and urate possess neuroprotective properties, raising potential for disease-slowing effects.
Researchers have developed a method of lymphocytic vaccination to counter autoimmune diseases, proving clinically effective in treating multiple sclerosis and rheumatoid arthritis. The technology involves creating an immunology cell bank to enhance immunological protection against infection.
Researchers have identified RasGRP1 as a key cause of Parkinson's dyskinesia, a debilitating side effect of dopamine replacement therapy. Inhibiting RasGRP1 production in the brain can diminish involuntary movements without negating the useful effects of dopamine therapy.
Researchers identified two distinct protein shapes associated with Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. The discovery may lead to improved diagnosis and treatment of these age-related conditions.
Researchers at Duke University have successfully treated motor dysfunction in an animal model of Parkinson's disease using light-based deep brain stimulation. The technique, which targets specific neurons, shows promise for tailoring therapies to individual patients and improving treatment outcomes.
Researchers have mapped out cell types behind various brain disorders, including Parkinson's disease, indicating that the disease may start in the gut. Oligodendrocytes were found to be affected early on, suggesting they play a key role in the early stages of the disease.
Researchers found signs of autoimmunity in Parkinson's patients years before diagnosis, providing potential for early detection and treatment. The study also showed that immune responses change over time, with more aggressive cells initially causing damage.
Researchers used network pharmacology to analyze Zhichan powder's effects on Parkinson's disease, identifying 18 major active components. This study provides new insights into the mechanism of action of Traditional Chinese Medicine prescriptions.
Researchers found epigenetic differences between brain hemispheres linked to variations in gene activity, making one side more vulnerable to neurological diseases. These findings could lead to new therapeutic strategies for treating Parkinson's and other neurological disorders.
Researchers have identified ATP10B as a novel risk gene for Parkinson's disease, revealing its role in transporting glucosylceramide, a lipid critical to the disease's pathogenesis. Mutations in this gene can lead to neuronal loss and increased sensitivity to environmental risk factors.
A Rutgers University study found that cognitive behavioral therapy can help alleviate depression and improve quality of life for people with Parkinson's disease. The treatment was individually tailored to target negative thoughts and behaviors, resulting in improved mental health status for 40% of participants.
A study published in Neurology found that phone-based cognitive-behavioral therapy significantly improves depression, anxiety, and quality of life in people with Parkinson's disease. After three months of weekly sessions, participants showed a significant reduction in depression symptoms and maintained improvements six months later.
Researchers found no significant difference in Parkinson's disease progression between those taking isradipine and placebo. Despite its neuroprotective properties in animal models, the study didn't support the hypothesis that isradipine slows early-stage Parkinson's progression.
Researchers developed a novel technique to study how deformed microtubules affect their function, shedding light on traumatic brain injuries and Parkinson's disease. Microtubules, like train tracks, transport molecular cargo, but become deformed in certain diseases.
Researchers found that natural killer cells can regulate and restrain inflammation of brain tissue, reducing protein clumping and viral resistance. The study suggests NK cells play a critical role in protecting against Parkinson's disease progression.
Researchers discovered a link between Parkinson's and reduced activity of a gene targeted by blue-green algae neurotoxin. This finding highlights the potential role of environmental toxins in neurodegenerative diseases like Parkinson's.
A study published in Neurology found that 82% of people with Parkinson's reported one or more eye problems, compared to 48% without the disease. Eye problems often interfered with daily life for 68% of those with Parkinson's, affecting activities like driving and reading.
Researchers discovered a new master control region in alpha-synuclein protein that controls amyloid formation, leading to neurodegeneration and movement difficulties. This finding opens up new opportunities to develop therapies to slow down or prevent Parkinson's disease.
Researchers investigated the association between stress-related disorders and neurodegenerative diseases in Sweden's national health registers. Stress-related disorders were found to be associated with an increased risk of these diseases.
A preliminary study found that Rock Steady Boxing participants reported significant improvements in quality of life areas, including depression, fatigue, and fear of falling. The program also boosted confidence in exercising, with current participants scoring better on standardized scales than non-participants.
A study found that NLX-112 reduced dyskinesia and improved movement symptoms in marmosets with Parkinson's-like symptoms. The results suggest that the drug has potential as a future treatment for people with Parkinson's, offering hope for those affected by debilitating movement problems.
Researchers used gene-editing tools to introduce the Parkinson's mutation into marmoset monkey stem cells, creating a primate model for studying disease progression and testing therapies. The edited cells exhibited characteristics of Parkinson's, such as abnormal cellular chemistry and reduced connections with neighboring neurons.
People with mild to moderate Parkinson's disease showed significant improvements in speech, handwriting, and motor skills after playing pingpong once a week for six months. The study found that participants experienced reductions in symptoms such as tremors, rigidity, and balance problems.
A new study by UCL researchers has found a link between iron accumulation in the brain and cognitive decline in people with Parkinson's disease. The study used advanced MRI techniques to detect iron deposits in different brain regions, revealing associations with poor memory and thinking scores.
Researchers have successfully solved the structure of Parkinson's disease-related protein LRRK2 inside cells using a pioneering technique. The study reveals that pathogenic LRRK2 forms exquisitely-organized double-helices around microtubules, suggesting a potential target for therapies.
Researchers have discovered a promising molecule, BT13, that may slow or stop Parkinson's disease. By increasing dopamine levels and protecting brain cells, BT13 has shown promise in treating the condition.
Researchers at Trinity College Dublin have discovered that the overactive LRRK2 enzyme wreaks havoc on motor and cognitive abilities in Parkinson's disease. The team has simulated the activity of the enzyme in the laboratory, visualizing its effects on protein complexes and paving the way for new treatments.
A long-term study of 200,000 long-distance skiers found they were almost 30% less likely to develop Parkinson's disease. This 'motor reserve' dissipates with time and age.
A randomized clinical trial found that outpatient palliative care was associated with better patient and caregiver outcomes for patients with Parkinson disease. The study included 210 patients and 175 caregivers and examined the effects of palliative care on quality of life, mood, and sleep.
Researchers have developed a technology that can distinguish between Parkinson's disease and multiple system atrophy with high accuracy. The Protein Misfolding Cyclic Amplification (PMCA) test targets misfolded alpha-synuclein aggregates, allowing doctors to identify the correct disease and pursue timely treatment.
Researchers found that people with Parkinson's carrying APOE4 variant experience faster cognitive decline and more severe dementia. Targeting APOE may reduce dementia risk in Parkinson's patients.
A Danish registry study found a significant association between neurological disorders, including dementia and Parkinson's disease, and increased risk of suicide. The study analyzed nearly 40 years of data for 7.3 million people, revealing that those with neurological conditions were more likely to die by suicide.
A recent study by KU Leuven researchers has discovered a link between a defective ATP13A2 gene and cell death in Parkinson's disease. The study found that the gene plays a crucial role in transporting polyamines, essential molecules supporting various cellular functions.
The Parkinson's Foundation has awarded a total of $30,000 to three physical therapists through its new Physical Therapy Faculty Award. The award will support individual project initiatives aimed at improving life for people with Parkinson's disease, including developing academic partnerships and heart rate monitoring protocols.
A collaboration between Rutgers University and Scripps Research has led to the discovery of a small molecule that reduces α-synuclein protein levels, potentially slowing or stopping Parkinson's disease progression. This finding offers hope for early-stage patients and may be applicable to other neurodegenerative diseases like Alzheimer's.
Researchers at Cedars-Sinai Medical Center found that people with Parkinson's disease before age 50 were born with disordered brain cells. The study suggests a potential new treatment using PEP005, which reduced alpha-synuclein levels and countered abnormal enzyme activity in dopamine neurons.
A study published in Environmental Health found a link between air pollution from traffic and an increased risk of developing dementia, Parkinson's disease, Alzheimer's disease, and multiple sclerosis. Living near green spaces appears to have protective effects against these neurological disorders.
Researchers at Cold Spring Harbor Laboratory have developed a chemical compound, UBP1700, that inhibits certain NMDARs while allowing others to function. This allows for the precise investigation of NMDAR activity in both healthy and diseased brains.
Scientists have discovered a non-invasive technique that can successfully target both cholinergic and dopaminergic neurons, two major neurotransmitter systems affected by Parkinson's disease. This breakthrough could lead to a more precise and effective treatment for the condition.
A study led by University at Buffalo biologist Shermali Gunawardena has explored the properties of alpha-synuclein, a protein associated with Parkinson's disease. The research suggests that deleting a specific region of the protein may help prevent key problems that occur when too much alpha-synuclein is produced.
Researchers have identified a probiotic that slows and reverses the build-up of alpha-synuclein protein, which is associated with Parkinson's disease. The probiotic, Bacillus subtilis, produces chemicals that change how enzymes process specific fats, preventing toxic clumps from forming.
A UK-wide trial has started recruiting patients for a three-year study on preventing falls in people with Parkinson's disease, led by the Royal United Hospitals Bath NHS Foundation Trust and the University of Bristol. The trial will test whether a commonly prescribed dementia drug can prevent debilitating falls and improve patients' qu...
Researchers propose a new computational analysis method that uses keystroke time series data to detect early stages of Parkinson's disease. The method, based on fuzzy recurrence plots, is less physically demanding than traditional testing methods and shows encouraging results.
Researchers discover a potential treatment for Parkinson's disease dyskinesias, a devastating side effect of long-term treatment. HU-308 reduces involuntary movements and improves symptoms in mice, offering a safer alternative to medicinal cannabis.
Researchers found that a weekly multi-modal regime combining physical and cognitive exercises significantly improved motor and non-motor symptoms in Parkinson's patients. The study suggests tailored exercise programs could improve quality of life for those affected by the disease.
A recent clinical trial found that nilotinib increases dopamine levels and reduces neurotoxic proteins in people with Parkinson's disease. The study also showed potential in halting motor and non-motor decline, making it a promising treatment option.
The Defitech Foundation has teamed up with EPFL, CHUV and UNIL to develop innovative therapies for paraplegic and quadriplegic patients. Researchers will trial personalized treatments that use electrical stimulation to restore motor function.
A clinical trial found nilotinib to be safe and tolerable for patients with moderate to advanced Parkinson's disease, but did not show a clinically meaningful benefit. The study, led by Northwestern University, involved 76 participants and tested three doses of the medication over six months.
Chaperone proteins protect α-Synuclein from cell damage in healthy cells. Impaired chaperone binding leads to α-Synuclein accumulation and mitochondrial destruction, characteristic of Parkinson's disease. The study provides new insights into the role of molecular bodyguards in neurodegenerative disorders.